Skip to content
logo MSD Oncology Clinical Trials
  • Home
  • Trials
    • Main Menu
    • Trial Overview
    • Bladder
    • Breast
    • Colorectal
    • Esophageal
    • Gastric
    • Gynecologic
    • Head and Neck
    • Hematologic
    • Kidney
    • Liver and Bile Duct
    • Lung
    • Melanoma
    • Pediatric
    • Prostate
    • Solid Tumors
  • About
  • Common Questions
  • For HCPs
  • English
    • Back
    • English
    • English (AU)
    • Español (LatAm)
    • Français (FR)
    • Português (BR)

Trial Drug: 5-FU

The purpose of this study is to assess the efficacy and safety of pembrolizumab plus lenvatinib plus chemotherapy compared with pembrolizumab plus chemotherapy as first-line intervention in participants with metastatic esophageal carcinoma

The primary hypotheses are that pembrolizumab plus lenvatinib plus chemotherapy is superior to pembrolizumab plus chemotherapy with respect to overall survival (OS) and progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR).

Trial Drug: 5-FU

Efficacy and Safety of Pembrolizumab Plus Lenvatinib Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma

March 10, 2022

By Tyler Kalist

The purpose of this study is to assess the efficacy and safety of pembrolizumab plus lenvatinib plus chemotherapy compared with pembrolizumab plus chemotherapy as first-line intervention in participants with metastatic esophageal

Efficacy and Safety of Lenvatinib Plus Pembrolizumab Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma

March 10, 2022

By Support_Clique

The purpose of this study is to assess the efficacy and safety of lenvatinib (E7080/MK-7902) plus pembrolizumab (MK-3475) plus chemotherapy compared with chemotherapy alone in participants with advanced/metastatic gastroesophageal cancer. The

Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

March 10, 2022

By Tyler Kalist

The study will compare the efficacy and safety of pembrolizumab plus trastuzumab in combination with standard of care (SOC) chemotherapy versus trastuzumab in combination with SOC chemotherapy in participants with HER2-positive

Efficacy and Safety of Olaparib With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer

March 7, 2022

By clique_admin

This is an efficacy and safety study of olaparib alone or in combination with bevacizumab being compared to bevacizumab with a fluoropyrimidine in participants with unresectable or metastatic colorectal cancer who

Study of Pembrolizumab Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy

March 7, 2022

By clique_admin

The purpose of this study is to assess the efficacy and safety of treatment with definitive chemoradiotherapy (dCRT) + pembrolizumab (MK-3475) compared to treatment with dCRT + placebo with respect to

logo-white MSD Oncology Clinical Trials
  • MSD Privacy Policy
  • Terms of Use
  • Cookie Preferences
  • Accessibility

Copyright © 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.

eSSENTIAL Accessibility

eSSENTIAL Accessibility